Cystic Fibrosis Therapeutics Market By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, and CFTR Modulators), By Route of Administration (Oral Drugs and Inhaled Drugs), and By Region - Trends, Analysis, and Forecast till 2029

Cystic Fibrosis Therapeutics Market accounted for USD 5.3 Billion in 2019 and is estimated to be USD 25.6 Billion by 2029 and is anticipated to register a CAGR of 17.2%

Cystic fibrosis is a hereditary disorder, which highly affects the lungs and other body parts such as liver, kidney, and pancreas. It is a mutation in an in the cystic fibrosis transmembrane conductance regulator (CFTR) gene a protein that regulates the movement of salts in and out of cells. However, mutation of this gene results to the absence of CFTR activity, which in turn alters the protein structure and results in loss of chloride. Patients undergo difficulty in breathing, fatty stool, mucus formation, and difficulty in the passageway of the pancreas, intestine, bile duct, & salivary gland. Cystic fibrosis is detected by the usage of a sweat test and genetic testing. Treatment of cystic fibrosis includes physical therapy that helps in the reduction of mucus formation and fights against infections of an organ. Additionally, the use of drugs such as Pulmozyme, Kalydeco, and others. 

Growing prevalence of Cystic Fibrosis (CF)

According to the data published by the Cystic Fibrosis Foundation, the occurrence of these hereditary disorders is growing constantly. In 2015, in the U.S., there were 28,983 patients as compared to 26,366 patients in 2010. Swelling year-on-year growth in the number of patient’s additional results in the growing demand for efficient and effective CF therapeutics. Some of the commercially available approved drug class are Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, mucolytic drugs, bronchodilators drugs, anti-infective, anti-inflammatory drugs, antibiotics (oral, inhaled, or parental feeding formulae), and pancreatic enzyme supplements.

Growth in the number of initiatives concerning to development of NASH drugs

Favourable initiatives taken by regional and national nonprofit organizations is one of the key factors boosting the growth of the target market. These initiatives provide funding to CF patients. These organizations help in research & development activities of these therapeutics and improve the patient’s quality of life. For example, the North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to offer a collaborative and educational forum to CF professionals to share improvements in R&D related to CF therapeutics.

Conversely, higher cost of treatment and low awareness in developing nations are anticipated to hamper the growth of the cystic fibrosis therapeutics market during the forecast period.

The cystic fibrosis therapeutics market is segmented based on the drug class, route of administration, and region.

On the basis of the drug class, the cystic fibrosis therapeutics market is segmented into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Based on the route of administration, the target market is classified into oral drugs and inhaled drugs.

Regional Insights:

In the region, the cystic fibrosis therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America estimated for the highest revenue share in 2019, owing to growing number of patients suffering from cystic fibrosis. Additionally, initiatives taken by CF Foundation and Cystic Fibrosis Canada are one of the vital reasons that can be estimated for its maximum share. Asia Pacific is projected to be the fastest growing segment with a profitable growth rate. Moreover, growing awareness about CF disorders & treatment options is anticipated to fuel this segment throughout the forecast period. Improving healthcare facilities and economic development in this region and are projected to propel the market growth during the forecast period. Increasing awareness amongst healthcare professionals & patient population concerning advanced therapeutics in the market & their benefits over the existing drug portfolio is one of the essential factors expected to drive the market in the upcoming years. Currently, the presence of CF-specific drugs is low. Nevertheless, growing approvals and product launches in this market are projected to impel growth.

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029.  For the purpose of this study, has segmented the cystic fibrosis therapeutics market report based on drug class, route of administration, and region.

Cystic Fibrosis Therapeutics Market, By Drug Class:

• Pancreatic Enzyme Supplements
• Mucolytics, Bronchodilators
• CFTR Modulators

Cystic Fibrosis Therapeutics Market, By Route of Administration:

• Oral Drugs
• Inhaled Drugs

Cystic Fibrosis Therapeutics Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • U.S.
  • Canada

The key players operating in the cystic fibrosis therapeutics market include AbbVie Inc., Hoffmann-La Roche Ltd., Allergan, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Novartis AG, Alcresta Therapeutics Inc., AstraZeneca Plc., and Alaxia. The prominent players are constantly involved in the development of new or combination of products to treat cystic fibrosis. Investment in R&D is one of the planned measures to beat the competition. For instance, in February 2020, Allergan has entered into a definite agreement to sell Zenpep (pancrelipase), a therapy for exocrine pancreatic insufficiency due to cystic fibrosis (CF) and other conditions.

• AbbVie Inc.
• Hoffmann-La Roche Ltd.
• Allergan
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• Novartis AG
• Alcresta Therapeutics Inc.
• AstraZeneca Plc.
• Alaxia